Currently, the FDA-approved drugs available in the EGFR-NSCLC market include Telisotuzumab Vedotin (Teliso-V), Lazertinib (Leclaza), Nazartinib (EGF816), Patritumab deruxtecan (HER3-DXd), and many more.